ArticleNature medicine2023
Viral and host mediators of non-suppressible HIV-1 viremia.
Open access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 44 citations in OpenAlex.
- Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks.Journal of acquired immune deficiency syndromes (1999) · 2026Trial
- A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage.The Journal of infectious diseases · 2026Article
- 5' leader defects drive persistent HIV-1 viremia on long-term ART.Nature communications · 2026Article
- Article
- Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.The lancet. HIV · 2026Article
- Similar Changes in Proviral Landscapes Over 10 Years in 40 Individuals With Diverging HIV Reservoir Dynamics and Viral Load Kinetics.Open forum infectious diseases · 2026Article
- Elimination of Human Immunodeficiency Virus Reservoirs Harboring Intact Proviruses.The Journal of infectious diseases · 2026Article
- Article
- Residual HIV activity and host immunometabolic remodeling during antiretroviral therapy: implications for cardiovascular-kidney-metabolic risk.Frontiers in immunology · 2026Review
- Article
- Comparison of manual and automated ultrasensitive assays for residual HIV-1 in plasma from individuals on suppressive antiretroviral therapy.Journal of clinical microbiology · 2025Article
- Ultra-low level HIV p24 drives immune activation in antiretroviral therapy-treated people living with HIV.Communications medicine · 2025Article
- Superinfection promotes replication and diversification of defective HIV-1 proviruses in people with non-suppressible viraemia.Nature microbiology · 2025Article
- The Role of Integrated HBV DNA in the Quest for a Cure in HIV/HBV co-infection.Current HIV/AIDS reports · 2025Review
- A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage.bioRxiv : the preprint server for biology · 2025Article
- HIV-1 RNA in Large and Small Plasma Extracellular Vesicles: A Novel Parameter for Monitoring Immune Activation and Virological Failure.Journal of medical virology · 2025Article
- Impacts of immune checkpoint inhibitors use on the HIV reservoir are linked to provirus sequences but not integration sites.Scientific reports · 2025Article
- Proviruses in CD4Science translational medicine · 2025Article
- From network biology to immunity: potential longitudinal biomarkers for targeting the network topology of the HIV reservoir.Journal of translational medicine · 2025Review
Corrections and comments
- Update of
Authors and funding
40 authors at 7 institutions in 3 countries.
Abbas MohammadiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Behzad EtemadBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Xin ZhangBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yijia LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5300-0571
Gregory J BedwellDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Radwa SharafBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Autumn KittilsonBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Meghan MelbergBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Charles R CrainRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Anna K TraunbauerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Colline WongBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jesse FajnzylberBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0300-1255
Daniel P WorrallRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7760-9848
Alex RosenthalBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hannah JordanBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nikolaus JilgBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9154-2769
Clarety KasekeRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Francoise GiguelBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Xiaodong LianRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Rinki DeoBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Elisabeth GillespieBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rida ChishtiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sara AbrhaBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Taylor AdamsBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Abigail SiagianBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Dominic DorazioDivision of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Peter L AndersonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0001-6371-747X
Michael M LedermanDivision of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Sigal YawetzBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Daniel R KuritzkesBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mathias D LichterfeldBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9865-8350
Scott SiegDivision of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA.ORCID 0000-0002-1769-8682
Athe TsibrisBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2681-3216
Mary CarringtonRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-2692-2180
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Jose R Castillo-MancillaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Alan N EngelmanDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9709-2591
Gaurav D GaihaMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jli@bwh.harvard.edu.ORCID 0000-0001-9914-9662
Brigham and Women's Hospital · USRagon Institute of MGH, MIT and Harvard · USHarvard University · USUniversity Hospitals of Cleveland · USUniversity of Colorado Anschutz Medical Campus · USSimon Fraser University · CAUniversity of California, San Francisco · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MLeadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MThe impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4MWG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0MDelaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MProject 3. IntegrationU54AI170791 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Peter Cherepanov · 2022 to 2026
$30.6MBiochemical Mechanism of HIV DNA IntegrationR37AI039394 · NIAID · DANA-FARBER CANCER INST · PI Alan N. Engelman · 2010 to 2026
$10.2MHigh-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Athe M. Tsibris · 2022 to 2026
$10.1MMultidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MExploiting Highly Networked CTL Epitopes to Achieve a Functional HIV CureDP2AI154421 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GAIHA, GAURAV DAS · 2020 to 2024
$2.7MNCI NIH HHS 75N91019D00024NIAID NIH HHS DP2 AI154421NIAID NIH HHS P01 AI169768NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI060354NIAID NIH HHS R37 AI039394NIAID NIH HHS T32 AI007387NIAID NIH HHS U54 AI170791NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI164560
Abstract
Non-suppressible HIV-1 viremia (NSV) is defined as persistent low-level viremia on antiretroviral therapy (ART) without evidence of ART non-adherence or significant drug resistance. Unraveling the mechanisms behind NSV would broaden our understanding of HIV-1 persistence. Here we analyzed plasma virus sequences in eight ART-treated individuals with NSV (88% male) and show that they are composed of large clones without evidence of viral evolution over time in those with longitudinal samples. We defined proviruses that match plasma HIV-1 RNA sequences as 'producer proviruses', and those that did not as 'non-producer proviruses'. Non-suppressible viremia arose from expanded clones of producer proviruses that were significantly larger than the genome-intact proviral reservoir of ART-suppressed individuals. Integration sites of producer proviruses were enriched in proximity to the activating H3K36me3 epigenetic mark. CD4
Indexed as
HIV-1HIV InfectionsHIV SeropositivityCD4-Positive T-LymphocytesFemaleHumansMaleProvirusesRNA, ViralViral LoadViremiaRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.